Model-Informed Safety Management of Tocilizumab for Pediatric sJIA

A research document from figshare authored by Yujie Yang, last updated on June 1, 2026. It details a physiologically-based pharmacokinetic (PBPK) modeling study to determine optimal dosing and vaccination schedules for tocilizumab in children with systemic juvenile idiopathic arthritis (sJIA). The 612.7 KB document presents simulation results proposing specific dose-escalation regimens and recommended timing for live-attenuated vaccines.

Use Cases

• Informing pediatric dosing strategies based on simulated pharmacokinetic data for tocilizumab.
• Planning safe vaccination schedules for immunocompromised pediatric patients based on model-predicted drug washout periods.
• Validating PBPK model extrapolations from adults to pediatric populations using the described methodology.

Strengths

• Model predictions were within two-fold of observed pharmacokinetic data in children.
• Specific dose-escalation sequences are proposed for different patient weight groups (<30 kg and ≥30 kg).
• A clear recommended window (55 to 70 days) for live-attenuated vaccination after treatment cessation is provided.

Limitations

• The dataset is a 612.7 KB DOCX document, indicating a very limited scope of raw data.
• Row count and column-level documentation are absent; the primary content is a research summary.
• The data is model-simulated and should be validated with clinical observations.

Provenance

Source

figshare, author Yujie Yang.

Collection Method

Results from a physiologically-based pharmacokinetic (PBPK) modeling study, extrapolated from adults to pediatric patients.

Freshness

Last updated 2026-06-01 05:24:34